Migraine Medication Levadex – Awaiting FDA Approval, TEMPO Patent Granted
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
1. Aurora, Sheena K., MD; Silberstein, Stephen D., MD; Kori, Shashidhar H., MD; Tepper, Stewart J., MD; Borland, Scott W., MS; Want, Min, PhD; Dodick, David W., MD. "MAP004, Orally inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine." Headache 2011;51:507-517. 2. U.S. National Institutes of Health. "Glossary of Clinical Trials Terms." ClinicalTrials.gov. Last updated March 18, 2008. 3. Press Release. "MAP Pharmaceuticals Phase 3 Trial of Levadex(TM) Migraine Product Candidate Meets All Four Primary Endpoints." Mountain View, Calif. MAP Pharmaceuticals, Inc. May 26, 2009. 4. "Data from FREEDOM-301 Study for Levadex™ Orally Inhaled Migraine Drug Published in 'Headache.'" Mountain View, Calif. MAP Pharmaceuticals, Inc. April 7, 2011. 5. Press Release. "MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile." Mountain View, Calif. MAP Pharmaceuticals, Inc. Feb. 23, 2012. 6. Aurora, Sheena K., Kori, Shashidhar H., Barrodale, Pat, McDonald, Susan A. & Haseley, David (2006) "Gastric Stasis in Migraine: More Than Just a Paroxysmal Abnormality During a Migraine Attack." Headache 2006;46:57-63.